Rigel Pharmaceuticals, Inc. Stock price

Equities

RIGL

US7665596034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.48 USD -0.67% Intraday chart for Rigel Pharmaceuticals, Inc. +2.07% +2.07%
Sales 2024 * 148M Sales 2025 * 181M Capitalization 260M
Net income 2024 * -14M Net income 2025 * 10M EV / Sales 2024 * 1.75 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.43 x
P/E ratio 2024 *
-19.1 x
P/E ratio 2025 *
26.7 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.94%
More Fundamentals * Assessed data
Dynamic Chart
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating MT
Rigel Pharmaceuticals Seeks Acquisitions CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma CI
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications MT
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating MT
Transcript : Rigel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023
More news
1 day-0.67%
1 week+2.07%
Current month-2.63%
1 month-4.52%
3 months-5.13%
6 months+32.14%
Current year+2.07%
More quotes
1 week
1.40
Extreme 1.4
1.51
1 month
1.30
Extreme 1.3
1.73
Current year
1.08
Extreme 1.081
1.73
1 year
0.71
Extreme 0.712
1.96
3 years
0.64
Extreme 0.64
4.62
5 years
0.64
Extreme 0.64
5.50
10 years
0.64
Extreme 0.64
5.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 00-03-31
Director of Finance/CFO 61 18-05-28
Chief Tech/Sci/R&D Officer - 16-08-31
Members of the board TitleAgeSince
Chairman 65 17-11-01
Director/Board Member 73 05-09-30
Chief Executive Officer 63 00-03-31
More insiders
Date Price Change Volume
24-03-28 1.48 -0.67% 782,389
24-03-27 1.49 +4.93% 681,287
24-03-26 1.42 -1.39% 349,056
24-03-25 1.44 +1.41% 800,395
24-03-22 1.42 -2.07% 768,071

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.48 USD
Average target price
4.458 USD
Spread / Average Target
+201.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Rigel Pharmaceuticals, Inc. - Nasdaq